Cdkn2a_v2 (cyclin-dependent kinase inhibitor 2A, variant 2) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Cdkn2a_v2 (cyclin-dependent kinase inhibitor 2A, variant 2) Rattus norvegicus
Symbol: Cdkn2a_v2
Name: cyclin-dependent kinase inhibitor 2A, variant 2
RGD ID: 1578738
Description: transcript variant of Cdkn2a which is transcribed from an alternative promoter using the 1beta exon; involved in cell cycle regulation and tumorigenesis but does not bind Cdk4
INVOLVED IN cellular response to glucose stimulus; positive regulation of apoptotic process; response to caloric restriction; ASSOCIATED WITH acute myeloid leukemia (ortholog); B-lymphoblastic leukemia/lymphoma (ortholog); Breast Neoplasms (ortholog)
Type: splice  of Cdkn2a  
Previously known as: Arf; cyclin-dependent kinase inhibitor 2a p19Arf; p19ARF; translated in an alternative reading frame
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
Cytogenetic Map5q32NCBI

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process

Molecular Function


References - curated
# Reference Title Reference Citation
1. Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population. Askari M, etal., Mol Biol Rep. 2013 Aug;40(8):4921-8. doi: 10.1007/s11033-013-2592-5. Epub 2013 May 28.
2. Ocular expression and distribution of products of the POAG-associated chromosome 9p21 gene region. Chidlow G, etal., PLoS One. 2013 Sep 19;8(9):e75067. doi: 10.1371/journal.pone.0075067. eCollection 2013.
3. Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia. Cividin M, etal., Leuk Res. 2006 Oct;30(10):1273-8. Epub 2006 Mar 14.
4. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. Debies MT, etal., J Clin Invest. 2008 Jan;118(1):51-63.
5. Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells. Diaz-Rodriguez E, etal., Oncogene. 2012 Jun 7;31(23):2824-35. doi: 10.1038/onc.2011.458. Epub 2011 Oct 24.
6. Loss of p19Arf in a Rag1(-/-) B-cell precursor population initiates acute B-lymphoblastic leukemia. Hauer J, etal., Blood. 2011 Jul 21;118(3):544-53. doi: 10.1182/blood-2010-09-305383. Epub 2011 May 26.
7. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. Heidenreich A, etal., J Urol. 1998 May;159(5):1725-30.
8. Homozygous deletions of the INK4a/ARF locus in renal cell cancer. Kasahara T, etal., Anticancer Res. 2006 Nov-Dec;26(6B):4299-305.
9. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Kawamoto K, etal., Biochem Biophys Res Commun. 2006 Jan 20;339(3):790-6. Epub 2005 Nov 22.
10. Ink4a/Arf expression is a biomarker of aging. Krishnamurthy J, etal., J Clin Invest 2004 Nov;114(9):1299-307.
11. Alterations of P19ARF in rodent hepatoma cell lines but not in human primary liver cancer. Laes J, etal., Cancer Genet Cytogenet 2000 Mar;117(2):118-24.
12. A novel p16INK4A transcript. Mao L, etal., Cancer Res. 1995 Jul 15;55(14):2995-7.
13. Ribosomal biogenesis induction by high glucose requires activation of upstream binding factor in kidney glomerular epithelial cells. Mariappan MM, etal., Am J Physiol Renal Physiol. 2011 Jan;300(1):F219-30. doi: 10.1152/ajprenal.00207.2010. Epub 2010 Oct 13.
14. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Quelle DE, etal., Cell 1995 Dec 15;83(6):993-1000.
15. The INK4a /ARF locus: role in cell cycle control for renal cell epithelial tumor growth after the Chernobyl accident. Romanenko A, etal., Virchows Arch. 2004 Sep;445(3):298-304. Epub 2004 Jul 1.
16. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice. Shank-Calvo JA, etal., Oncogene. 2006 May 18;25(21):3023-31.
17. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Sharma G, etal., Life Sci. 2007 Apr 24;80(20):1873-81. Epub 2007 Feb 27.
18. Complex structure and regulation of the P16 (MTS1) locus. Stone S, etal., Cancer Res 1995 Jul 15;55(14):2988-94.
19. Role of the E2F1-p19-p53 pathway in ischemic acute renal failure. Tanaka H, etal., Nephron Physiol 2005;101(2):p27-34. Epub 2005 Jun 30.
20. Different p16INK4a and p14ARF expression patterns in acute myeloid leukaemia and normal blood leukocytes. Tschan MP, etal., Leuk Lymphoma. 2001 Sep-Oct;42(5):1077-87.
21. Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia. Volanakis EJ, etal., Blood. 2009 Nov 12;114(20):4451-9. doi: 10.1182/blood-2009-07-233346. Epub 2009 Sep 16.
22. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Williams RT, etal., Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6688-93. Epub 2006 Apr 17.
23. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Zhang Z, etal., Mod Pathol. 2006 Oct;19(10):1339-43. Epub 2006 Jun 23.




Protein Sequences
GenBank Protein AAL76336 (Get FASTA)   NCBI Sequence Viewer  
  AAL76337 (Get FASTA)   NCBI Sequence Viewer  
  AAT92509 (Get FASTA)   NCBI Sequence Viewer  
  Q8QZZ9 (Get FASTA)   NCBI Sequence Viewer  

Additional Information

Database Acc Id Source(s)
NCBI Gene Cdkn2a_v2

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2006-04-26 Cdkn2a_v2  cyclin-dependent kinase inhibitor 2A, variant 2      Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_protein use of alternative promoters and alternative first exons for variant 1 (Cdkn2a) and variant 2 (p19Arf), both of which contain translation start sites, results in the production of two non-homologous proteins despite the fact that the transcripts share two downstream exons (exons 2 and 3)